Efficacy and safety of isavuconazole for invasive fungal infections: A systematic review and meta-analysis of randomized controlled trials
Medical Mycology · 30.09.2025 · 63 (10)
DOI: 10.1093/mmy/myaf089 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Medical Mycology, online erschienen am 27.09.2025. Verfasst von Ayano Kawasaki und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacodynamics, Keio University Faculty of Pharmacy, 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8512, Japan. Hauptthemen laut MEDLINE: Invasive Fungal Infections, Antifungal Agents, Nitriles, Pyridines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Isavuconazole (ISA) is a treatment option for invasive fungal infections (IFIs) and is known for a favorable safety profile compared with other antifungal agents. However, comprehensive evidence regarding its efficacy and safety remains limited.
Objectives
This study aimed to assess the efficacy and safety of ISA compared with other antifungal agents through a systematic review and meta-analysis restricted to randomized controlled trials (RCTs), to provide more reliable estimates of its clinical effects.
Methods
Following Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) guidelines, a comprehensive literature search was conducted using PubMed, the Cochrane Library, Web of Science, and ClinicalTrials.gov to identify RCTs comparing ISA with other antifungal agents. The primary outcomes were clinical response and mortality. Secondary outcomes included the incidence of adverse events, including serious, drug-related, and organ-specific toxicities. A subgroup analysis was conducted focusing on filamentous fungal infections, comparing ISA and voriconazole.
Results
Three RCTs met the inclusion criteria. No statistically significant differences were observed between ISA and comparator agents in terms of clinical response, mortality, or total and organ-specific adverse events. A trend toward fewer adverse events was noted in the ISA group. In the subgroup analysis, ISA and voriconazole showed similar efficacy and overall safety; however, the incidence of both drug-related adverse events and hepatobiliary disorders was significantly lower in the ISA group.
Conclusions
ISA demonstrated efficacy comparable to that of other antifungal agents, with a favorable safety profile in patients with IFIs, including filamentous fungal infections. This meta-analysis of RCTs provides high-quality evidence to support antifungal drug selection in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pharmacodynamics, Keio University Faculty of Pharmacy, 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8512, Japan.
- Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8553, Japan.
ORCID-Profile: Yuki Igarashi
Zitieren
APA
Kawasaki, A., Shintani, R., Takao, R., Nakazawa, Y., Mihara, T., Ikegami, S., Shimada, S., Matsumoto, Y., Okamoto, Y., Igarashi, Y., Enoki, Y., Taguchi, K., & Matsumoto, K. (2025). Efficacy and safety of isavuconazole for invasive fungal infections: A systematic review and meta-analysis of randomized controlled trials. Medical Mycology, 63(10). https://doi.org/10.1093/mmy/myaf089
Vancouver
Kawasaki A, Shintani R, Takao R, Nakazawa Y, Mihara T, Ikegami S, et al. Efficacy and safety of isavuconazole for invasive fungal infections: A systematic review and meta-analysis of randomized controlled trials. Medical Mycology. 2025;63(10). doi:10.1093/mmy/myaf089
BibTeX
@article{Kawasaki2025,
author = {Kawasaki, Ayano and Shintani, Ryuya and Takao, Risa and Nakazawa, Yuka and Mihara, Takayuki and Ikegami, Shintaro and Shimada, Sora and Matsumoto, Yuri and Okamoto, Yuko and Igarashi, Yuki and Enoki, Yuki and Taguchi, Kazuaki and Matsumoto, Kazuaki},
title = {Efficacy and safety of isavuconazole for invasive fungal infections: A systematic review and meta-analysis of randomized controlled trials},
journal = {Medical Mycology},
year = {2025},
volume = {63},
number = {10},
doi = {10.1093/mmy/myaf089}
}
EUVIMED